Andrew Kuykendall, MD, discusses data from a phase 2 trial of fedratinib for the treatment of myeloproliferative neoplasms.

Positive phase 3 results from the CAN-2409 clinical trial in intermediate-to-high risk localized prostate cancer have been selected for an oral presentation at the upcoming 2025 ASCO Annual Meeting, ...

In April 2025, our partner Jazz announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of ...

Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash ...

This fundamental study explores a novel cellular mechanism underlying the degeneration of locus coeruleus neurons during chronic restraint stress. The evidence supporting the overexpression of LC ...

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

The inner ear contains distinct sensory organs, produced sequentially by segregation from a large sensory-competent domain in the developing otic vesicle. To understand the mechanistic basis of this ...

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

Major Cause of Inflammatory Bowel Disease Discovered June 5, 2024 — Researchers have discovered a new biological pathway that is a principal driver of inflammatory bowel disease (IBD ...

Diabetes mellitus (DM) is a widespread metabolic disorder with profound effects on vital organs. Often referred to as a “systemic” or “multi-organ” disorder due to the impact on key organs, such as ...